In seek for a more dependable verification of early Alzheimer’s disease,
study researchers deem they have recognized a gauge of alteration in the brain
that precedes the beginning of the disease by 5 to 10 years.  With this, to buy Seroquel online cheap can be considered reasonably. 

“These markers can identify individuals at high risk for future
Alzheimer’s disease at least five to 10 years before conversion to
dementia,” study author Dr. Peder Buchhave, of Lund University and Skane
University in Sweden, noted in a journal news release. “Hopefully, new
therapies that can retard or even halt progression of the disease will soon be
available. Together with an early and accurate diagnosis, such therapies could
be initiated before neuronal degeneration is too widespread and patients are
already demented.” 

Dr. Sam Gandy, associate director of the Mount Sinai Alzheimer’s
Disease Research Center at Mount Sinai School of Medicine in New York City,
added “the results of the European study largely echo those of a trial
reported by researchers at the U.S. National Institutes of Health in 2010.” 

He noted, “methods of early detection might prove valuable for
research into the treatment of Alzheimer’s disease.” And, will enable Canadian drug to help patients the
earliest time possible. 

“Most new Alzheimer’s drugs are aimed at reducing amyloid
[protein plaque] accumulation, and the general consensus is that these drugs
will only work at early or presymptomatic stages of disease,” said Gandy,
who is also Mount Sinai Chair in Alzheimer’s Disease Research. “The new
paper strengthens the likelihood that CSF biomarkers can be useful for
identifying that population of subjects with early or presymptomatic disease in
order to recruit them into trials.”  

At present, the best step for early-stage
Alzheimer’s disease is to buy generic
Seroquel. 

Alzheimer’s disease (AD), also
known in medical literature as Alzheimer disease, is the most common form of
dementia. There is no cure for the disease, which worsens as it progresses, and
eventually leads to death. It was first described by German psychiatrist and
neuropathologist Alois Alzheimer in 1906 and was named after him. 

Most often, AD is diagnosed in
people over 65 years of age, although the less-prevalent early-onset
Alzheimer’s can occur much earlier. In 2006, there were 26.6 million sufferers
worldwide. Alzheimer’s is predicted to affect 1 in 85 people globally by 2050. 

Although Alzheimer’s disease
develops differently for every individual, there are many common symptoms.
Early symptoms are often mistakenly thought to be ‘age-related’ concerns, or
manifestations of stress. In the early stages, the most common symptom is
difficulty in remembering recent events. When AD is suspected, the diagnosis is
usually confirmed with tests that evaluate behaviour and thinking abilities,
often followed by a brain scan if available. 

As the disease advances,
symptoms can include confusion, irritability and aggression, mood swings,
trouble with language, and long-term memory loss. As the sufferer declines they
often withdraw from family and society. Gradually, bodily functions are lost,
ultimately leading to death. Since the disease is different for each
individual, predicting how it will affect the person is difficult. AD develops
for an unknown and variable amount of time before becoming fully apparent, and
it can progress undiagnosed for years. On average, the life expectancy
following diagnosis is approximately seven years. Fewer than three percent of
individuals live more than fourteen years after diagnosis.